ProHealth health Vitamin and Natural Supplement Store and Health
Home  |  Log In  |  My Account  |  View Cart  View Your ProHealth Vitamin and Supplement Shopping Cart
800-366-6056  |  Contact Us  |  Help
Facebook Google Plus
Fibromyalgia  Chronic Fatigue Syndrome & M.E.  Lyme Disease  Natural Wellness  Supplement News  Forums  Our Story
Store     Brands   |   A-Z Index   |   Best Sellers   |   New Products   |   Deals & Specials   |   Under $10   |   SmartSavings Club

Trending News

Inflammation Disrupts Memory - What Can You Do to Protect Your Brain?

All About Ginkgo Biloba: Benefits of This Timeless Herbal Supplement

Yarrow Oil: Here's Why It Deserves a Place in Your First-Aid Kit

Artificial sweeteners linked to risk of weight gain, heart disease and other health issues

Vitamin D supplement use associated with lower risk of breast cancer

Carnitine deficiency suggested as contributor to autism

Hop Oil: A Safe Sleep Aide

Lutein — An Important Nutrient for Eye and Brain Health

White Camphor Oil: The Purest Camphor Oil

Taurine: Facts About This Crucial Amino Acid

 
Print Page
Email Article

Stanford Study Shows Now-Familiar Medications at Core of Better Outlook for Depressed Patients

  [ 544 votes ]   [ Discuss This Article ]
www.ProHealth.com • April 30, 2002




STANFORD, Calif. - Enough Americans suffer from depression to fill Yankee Stadium 330 times over, and while depression rates continue to rise, people with the illness have reason to be hopeful. A new study shows that doctors are treating the disease more than ever before - thanks in part to the newest category of antidepressant medication.

"Our study confirms the belief that the diagnosis and treatment of depression have been impacted by the advent of selective serotonin reuptake inhibitors (SSRIs)," said Randall Stafford, MD, assistant professor of medicine at Stanford University School of Medicine and lead author of the latest report. "Findings show that the quality of care received by depressed patients has improved since the introduction of this class of medications in 1988." The study appeared in the April 29 issue of the Primary Care Companion to the Journal of Clinical Psychiatry.

SSRIs are one of several categories of antidepressants. Although medications in each category are effective in treating the disease, SSRIs (including well-known brands such as Prozac, Paxil and Zoloft) have fewer side effects than the others. Stafford noted that patients who take other types also face a greater risk of overdose, along with more side effects such as weight gain, stomach irritation and dry mouth.

The safety profile and relatively limited side effects of SSRIs make them attractive to both physicians and patients, Stafford said, and as a result they are the most prescribed category of antidepressant in the country. Stafford's team conducted the study to examine the drugs' popularity among physicians and to more closely examine their impact on treatment of depressive illness.

"Past studies have focused on broader changes in depression treatment, but we wanted to go beyond this and look at the relationship between SSRIs and other medications," he said. "There was a perception that treatment had changed since the advent of SSRIs, and we wanted objective information to go along with this."

To analyze prescribing trends, Stafford turned to diagnosis and treatment data from the National Disease and Therapeutic Index, a survey of office-based physicians. Stafford and his team selected visits by patients with depression-related diagnoses over the period of 1989 to early 2001; the sample of visits ranged from 3,901 in 1989 to 6,385 in 2000.

After analyzing the data, Stafford found that 70 percent of patients diagnosed with depression in 1987 (the year before SSRIs were introduced) were treated with antidepressant medication, while 89 percent were treated with medication in 2001.

The type of antidepressant prescribed changed dramatically over this time period as well. In 1987, the most commonly prescribed drugs were from a group known as tricyclics; of the treated patients, 47 percent were given this type. By 2000, only 2 percent of patients received tricyclics.

The study shows that SSRIs were rapidly adopted by physicians - in 1989, after just one year on the market, Prozac was prescribed to 21 percent of patients. Within six years of introduction SSRIs were the most highly prescribed type for depression. Stafford said this is unusual because physicians often "take their time to fully adopt recommended drugs."

"There is a perception that SSRIs are definitively better - even though they've never been shown to treat depression more effectively than other antidepressants," he said. "The perceived superiority probably stems from the drugs' fewer side effects, their promotion by manufacturers and greater public acceptance of these medications."

The study also shows that the number of physician visits by patients for depression increased from 14.4 million in 1987 to 24.5 million in 2001. Although Stafford said this increase was likely due to a number of factors, the advent of SSRIs certainly played a major role. "If you don't have medications you feel comfortable prescribing, your motivation for diagnosing someone as depressed is lower," he said. "Physicians feel comfortable with the treatment options so they're more likely to diagnose and treat their patients."

Stafford noted that past studies have shown that depression is widely underdiagnosed and undertreated in the United States, so the increase in the number of people being treated is encouraging. "SSRIs are helping to improve the quality of care for people suffering from depression," he said.


Stanford University Medical Center integrates research, medical education and patient care at its three institutions - Stanford University School of Medicine, Stanford Hospital & Clinics and Lucile Packard Children's Hospital. For more information, please visit the Web site of the medical center's Office of Communication & Public Affairs at http://mednews.stanford.edu.



Post a Comment

Featured Products From the ProHealth Store
Optimized Curcumin Longvida® Ultra EPA  - Fish Oil Energy NADH™ 12.5mg


Article Comments



Be the first to comment on this article!

Post a Comment


 
NAD+ Ignite with Niagen

Featured Products

Vitamin D3 Extreme™ Vitamin D3 Extreme™
50,000 IU Vitamin D3 - Prescription Strength
Energy NADH™ 12.5mg Energy NADH™ 12.5mg
Improve Energy & Cognitive Function
Optimized Curcumin Longvida® Optimized Curcumin Longvida®
Supports Cognition, Memory & Overall Health
FibroSleep™ FibroSleep™
The All-in-One Natural Sleep Aid
Ultra EPA  - Fish Oil Ultra EPA - Fish Oil
Ultra concentrated source of essential fish oils

Natural Remedies

Aches and Pains? A Simple Solution You'll Love Aches and Pains? A Simple Solution You'll Love
Inflammation Disrupts Memory - What Can You Do to Protect Your Brain? Inflammation Disrupts Memory - What Can You Do to Protect Your Brain?
Pioneer Scientists Uncover a Revolutionary Neuroprotective Supplement for Nerve Health Pioneer Scientists Uncover a Revolutionary Neuroprotective Supplement for Nerve Health
Vitamin E: Super Antioxidant We Only Thought We Knew Vitamin E: Super Antioxidant We Only Thought We Knew
Mitochondria-Booster NIAGEN® Shows Promise in First Human Clinical Trial Mitochondria-Booster NIAGEN® Shows Promise in First Human Clinical Trial

CONTACT US
ProHealth, Inc.
555 Maple Ave
Carpinteria, CA 93013
(800) 366-6056  |  Email

· Become a Wholesaler
· Vendor Inquiries
· Affiliate Program
SHOP WITH CONFIDENCE
Credit Card Processing
SUBSCRIBE TO OUR NEWSLETTERS
Get the latest news about Fibromyalgia, M.E/Chronic Fatigue Syndrome, Lyme Disease and Natural Wellness

CONNECT WITH US ProHealth on Facebook  ProHealth on Twitter  ProHealth on Pinterest  ProHealth on Google Plus

© 2017 ProHealth, Inc. All rights reserved. Pain Tracker App  |  Store  |  Customer Service  |  Guarantee  |  Privacy  |  Contact Us  |  Library  |  RSS  |  Site Map